These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: New protease inhibitor available through expanded access.
    Journal: Posit Aware; 1996; 7(6):7. PubMed ID: 11363981.
    Abstract:
    Agouron Pharmaceuticals is making their protease inhibitor, nelfinavir mesylate (Viracept), available in an expanded access program for people who are unable to use any of the three approved protease inhibitors due to intolerance, contraindication, or prior failure with those drugs. They must also have a CD4 count below 50. Viracept has already been studied in 500 patients, with the most frequent side effects being mild to moderate diarrhea, headache, and fatigue.
    [Abstract] [Full Text] [Related] [New Search]